Brief: Innate Pharma To Return US And EU Lumoxiti Commercialisation Rights To AstraZeneca

Innate Pharma SA

11/12/2020 06:14

Dec 11 (Reuters) - INNATE PHARMA SA  IPH.PA :
    * INNATE PHARMA TO RETURN US AND EU LUMOXITI
COMMERCIALIZATION
RIGHTS TO ASTRAZENECA
    * COMPANIES WILL DEVELOP A TRANSITION PLAN WITH GOAL OF
RETURNING
FULL COMMERCIALIZATION RESPONSIBILITIES TO ASTRAZENECA IN 2021
    * COMPANIES WILL ENSURE AVAILABILITY OF LUMOXITI TO PATIENTS
DURING TRANSITION PERIOD
    * INNATE WILL NO LONGER PURSUE LUMOXITI COMMERCIALIZATION
ACTIVITIES IN US OR EU; COMPANY TO RE-FOCUS INVESTMENTS IN ITS
RESEARCH AND DEVELOPMENT PORTFOLIO
    * COMPANIES WILL DEVELOP A TRANSITION PLAN, INCLUDING COSTS
AND
TRANSFER OF US MARKETING AUTHORIZATION AND DISTRIBUTION OF
LUMOXITI BACK TO ASTRAZENECA IN 2021
    * ALL OTHER AGREEMENTS WITH ASTRAZENECA REMAIN UNCHANGED
    * ACCOUNTING IMPACTS WILL BE PRESENTED IN DECEMBER 31, 2020
FINANCIAL STATEMENTS

Source text for Eikon:  ID:nGNX3m5XQG 
Further company coverage:  IPH.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))